Need Help?
Copied to clipboard!

Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies

This phase 2, single-arm study (NCT03682289) evaluated the efficacy and safety of the ATR inhibitor ceralasertib in patients with ARID1A-deficient advanced solid tumors. Based on the synthetic lethal relationship between ARID1A loss and ATR inhibition, the study enrolled 30 patients (29 evaluable) with confirmed ARID1A protein loss via immunohistochemistry (IHC). The cohort included patients with various malignancies, most notably ovarian clear cell carcinoma (OCCC), endometrioid endometrial carcinoma (EC), and pancreatic ductal adenocarcinoma.

Molecular technologies employed to characterize these tumors included clinical next-generation sequencing (NGS) for somatic and germline mutations, bulk RNA-seq for transcriptomic analysis, and cyclic immunofluorescence (CycIF) for detailed immune profiling of the tumor microenvironment.

We observed a confirmed objective response rate (ORR) of 14% overall, and an ORR of 33% specifically in OCCC and EC patients, with a median response duration of 33.7 months in this subset. Exploratory analyses linked clinical response to the upregulation of G2/M checkpoint and DNA double-strand break-sensing pathways. Furthermore, responders showed a depletion of HLAII+ CD163+ macrophages/monocytes in pretreatment tumors. The safety profile was manageable, with reversible cytopenias being the most common high-grade adverse events.

Data available through dbGaP includes the raw RNA-seq FASTQ files generated from tumor specimens.